In its annual report for the fiscal year ended 30 April 2016, Consort Medical reports that its subsidiary Bespak experienced revenue growth of almost 11%, and CDMO Aesica, which Consort acquired in November 2014, experienced “significant growth” and “encouraging EBIT margin growth.” Overall revenue for Consort was up 50.4% to £276.9 million.
Bespak’s MDI growth was especially strong, particularly in valve sales, with an increase of 7.1%. For DPIs, revenue growth was 1.6%. According to the company, MDIs make up over 51% of Bespak sales, with DPIs representing just over 31% of sales.
Among the operational highlights the company cites are the revelation that Bespak’s DEV610 DPI is the device used for Mylan’s generic version of Advair, that Bespak has added a development program for Sandoz’s Aeropharm inhalation company, and an “enthusiastic market response” to the new Bespak/Aesica joint service offering. In June 2014, Consort announced that it was adding a 5,200 sq m facility to its King’s Lynn location for manufacture of the DEV610 device.
In its update on the DEV200 inhaler for Nicoventures’ nicotine inhaler, Consort cautions that, “the Voke inhaler is a technically complex design which presents a number of challenges. We remain committed to the delivery of the product for successful launch, which we are hopeful of in the next 12 months.”
Read the Consort Medical results.
